Hossein Borghaei

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 27

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

JCO precision oncology

The oncologist

Cancer

Fox Chase Cancer Center

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Fox Chase Cancer Center Jun 30 2002

United States

Professor and Chief, Thoracic Oncology :: Hematology and Oncology

Publications

Joel W Neal, Katherine Minichiello, Ryan C Brennick, Richard S P Huang, Matthew C Hiemenz, Cornel Amler, Jyoti Patel, Roy S Herbst, Karen L Reckamp, Hossein Borghaei, Louise Highleyman, Mary W Redman, Lincoln W Pasquina, David E Kozono
A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol. The oncologist 29 (6) (2024)
Abdul Rafeh Naqash, Charalampos S Floudas, Etan Aber, Asaf Maoz, Amin H Nassar, Elio Adib, Khalil Choucair, Joanne Xiu, Yasmine Baca, Biagio Ricciuti, Joao M Victor Alessi, Mark M Awad, Chul Kim, Julia Judd, Luis E Raez, Gilberto de Lima Lopes, Jorge J Nieva, Hossein Borghaei, Naoko Takebe, Patrick C Ma, Balazs Halmos, David J Kwiatkowski, Stephen V Liu, Hirva Mamdani
Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11 -Mutant Non-Small-Cell Lung Cancer. JCO precision oncology 8 (2024)
Afshin Dowlati, Horst-Dieter Hummel, Stephane Champiat, Maria Eugenia Olmedo, Michael J Boyer, Kai He, Neeltje Steeghs, Hiroki Izumi, Melissa Lynne Johnson, Tatsuya Yoshida, Hasna Bouchaab, Hossein Borghaei, Enriqueta Felip Font, Philipp J Jost, Shirish M Gadgeel, Xi Chen, Youfei Yu, Pablo Martinez, Amanda Parkes, Luis G Paz-Ares
Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Joel W Neal, Katherine Minichiello, Ryan C Brennick, Richard S P Huang, Matthew C Hiemenz, Cornel Amler, Jyoti Patel, Roy S Herbst, Karen L Reckamp, Hossein Borghaei, Louise Highleyman, Mary W Redman, Lincoln W Pasquina, David E Kozono
A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol. The oncologist 29 (6) (2024)
Abdul Rafeh Naqash, Charalampos S Floudas, Etan Aber, Asaf Maoz, Amin H Nassar, Elio Adib, Khalil Choucair, Joanne Xiu, Yasmine Baca, Biagio Ricciuti, Joao M Victor Alessi, Mark M Awad, Chul Kim, Julia Judd, Luis E Raez, Gilberto de Lima Lopes, Jorge J Nieva, Hossein Borghaei, Naoko Takebe, Patrick C Ma, Balazs Halmos, David J Kwiatkowski, Stephen V Liu, Hirva Mamdani
Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11 -Mutant Non-Small-Cell Lung Cancer. JCO precision oncology 8 (2024)
Maishara Muquith, Magdalena Espinoza, Andrew Elliott, Joanne Xiu, Andreas Seeber, Wafik S El-Deiry, Emmanuel S Antonarakis, Stephanie L Graff, Michael J Hall, Hossein Borghaei, Dave S B Hoon, Stephen V Liu, Patrick C Ma, Rana R McKay, Trisha Wise-Draper, John Marshall, George W Sledge, David Spetzler, Hao Zhu, David Hsiehchen
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers. Nature cancer 5 (7) (2024)
May-Lucie Meyer, Fred R Hirsch, Paul A Bunn, Peter Ujhazy, David Fredrickson, Christine D Berg, David P Carbone, Balazs Halmos, Harpreet Singh, Hossein Borghaei, Andrea Ferris, Corey J Langer, Sanja Dacic, Tony S Mok, Solange Peters, Bruce E Johnson
Calls to action on lung cancer management and research. The oncologist (2024)
Tetyana Bagnyukova, Brian L Egleston, Valerii A Pavlov, Ilya G Serebriiskii, Erica A Golemis, Hossein Borghaei
Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non-small Cell Lung Cancers. Cancer research communications 4 (5) (2024)
Joel W Neal, Katherine Minichiello, Ryan C Brennick, Richard S P Huang, Matthew C Hiemenz, Cornel Amler, Jyoti Patel, Roy S Herbst, Karen L Reckamp, Hossein Borghaei, Louise Highleyman, Mary W Redman, Lincoln W Pasquina, David E Kozono
A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol. The oncologist 29 (6) (2024)
Joel W Neal, Katherine Minichiello, Ryan C Brennick, Richard S P Huang, Matthew C Hiemenz, Cornel Amler, Jyoti Patel, Roy S Herbst, Karen L Reckamp, Hossein Borghaei, Louise Highleyman, Mary W Redman, Lincoln W Pasquina, David E Kozono
A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol. The oncologist (2024)
Abdul Rafeh Naqash, Charalampos S Floudas, Etan Aber, Asaf Maoz, Amin H Nassar, Elio Adib, Khalil Choucair, Joanne Xiu, Yasmine Baca, Biagio Ricciuti, Joao M Victor Alessi, Mark M Awad, Chul Kim, Julia Judd, Luis E Raez, Gilberto de Lima Lopes, Jorge J Nieva, Hossein Borghaei, Naoko Takebe, Patrick C Ma, Balazs Halmos, David J Kwiatkowski, Stephen V Liu, Hirva Mamdani
Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11 -Mutant Non-Small-Cell Lung Cancer. JCO precision oncology 8 (2024)
Maishara Muquith, Magdalena Espinoza, Andrew Elliott, Joanne Xiu, Andreas Seeber, Wafik S El-Deiry, Emmanuel S Antonarakis, Stephanie L Graff, Michael J Hall, Hossein Borghaei, Dave S B Hoon, Stephen V Liu, Patrick C Ma, Rana R McKay, Trisha Wise-Draper, John Marshall, George W Sledge, David Spetzler, Hao Zhu, David Hsiehchen
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers. Nature cancer (2024)
Tetyana Bagnyukova, Brian L Egleston, Valerii A Pavlov, Ilya G Serebriiskii, Erica A Golemis, Hossein Borghaei
Synergy of EGFR and AURKA inhibitors in KRAS-mutated non-small cell lung cancers. Cancer research communications (2024)
Tetyana Bagnyukova, Brian L Egleston, Valerii A Pavlov, Ilya G Serebriiskii, Erica A Golemis, Hossein Borghaei
Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non-small Cell Lung Cancers. Cancer research communications 4 (5) (2024)
Abdul Rafeh Naqash, Charalampos S Floudas, Etan Aber, Asaf Maoz, Amin H Nassar, Elio Adib, Khalil Choucair, Joanne Xiu, Yasmine Baca, Biagio Ricciuti, Joao M Victor Alessi, Mark M Awad, Chul Kim, Julia Judd, Luis E Raez, Gilberto de Lima Lopes, Jorge J Nieva, Hossein Borghaei, Naoko Takebe, Patrick C Ma, Balazs Halmos, David J Kwiatkowski, Stephen V Liu, Hirva Mamdani
Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11 -Mutant Non-Small-Cell Lung Cancer. JCO precision oncology 8 (2024)
Tetyana Bagnyukova, Brian L Egleston, Valerii A Pavlov, Ilya G Serebriiskii, Erica A Golemis, Hossein Borghaei
Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non-small Cell Lung Cancers. Cancer research communications 4 (5) (2024)
Luis G Paz-Ares, Stephane Champiat, W Victoria Lai, Hiroki Izumi, Ramaswamy Govindan, Michael J Boyer, Horst-Dieter Hummel, Hossein Borghaei, Melissa Lynne Johnson, Neeltje Steeghs, Fiona Blackhall, Afshin Dowlati, Noemí Reguart, Tatsuya Yoshida, Kai He, Shirish M Gadgeel, Enriqueta Felip Font, Yiran Zhang, Amrita Pati, Mukul Minocha, Sujoy Mukherjee, Amanda Goldrick, Dirk Nagorsen, Nooshin Hashemi Sadraei, Taofeek Kunle Owonikoko
Tarlatamab, a First-In-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small Cell Lung Cancer: An Open-Label, Phase I Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Luis G Paz-Ares, Stephane Champiat, W Victoria Lai, Hiroki Izumi, Ramaswamy Govindan, Michael J Boyer, Horst-Dieter Hummel, Hossein Borghaei, Melissa Lynne Johnson, Neeltje Steeghs, Fiona Blackhall, Afshin Dowlati, Noemí Reguart, Tatsuya Yoshida, Kai He, Shirish M Gadgeel, Enriqueta Felip Font, Yiran Zhang, Amrita Pati, Mukul Minocha, Sujoy Mukherjee, Amanda Goldrick, Dirk Nagorsen, Nooshin Hashemi Sadraei, Taofeek Kunle Owonikoko
Tarlatamab, a first-in-class DLL3-targeted bispecific T cell engager, in recurrent small-cell lung cancer: an open-label, phase 1 study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Matthew R Zibelman, Alexander W MacFarlane, Kimberly Costello, Thomas McGowan, John O'Neill, Rutika Kokate, Hossein Borghaei, Crystal S Denlinger, Efrat Dotan, Daniel M Geynisman, Angela Jain, Lainie Martin, Elias Obeid, Karthik Devarajan, Karen Ruth, R Katherine Alpaugh, Essel Al-Saleem Dulaimi, Edna Cukierman, Margret Einarson, Kerry S Campbell, Elizabeth R Plimack
A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors. Nature communications 14 (1) (2023)
Apar Kishor Ganti, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Elie G Dib, Herbert L Duvivier, Eugene R Ahn, Deepti Behl, Hossein Borghaei, Ani S Balmanoukian, Anu Gaba, Rui Li, Kwabena Osei-Boateng, Ramya Thota, Gina N Grantham, Abigail Gregory, Susan Halabi, Richard L Schilsky
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO precision oncology 7 (2023)
Alessio Cortellini, Biagio Ricciuti, Hossein Borghaei, Abdul Rafeh Naqash, Antonio D'Alessio, Claudia A M Fulgenzi, Alfredo Addeo, Giuseppe L Banna, David James Pinato
Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. Cancer 128 (16) (2022)
Julie R Brahmer, Jong-Seok Lee, Tudor-Eliade Ciuleanu, Reyes Bernabe Caro, Makoto Nishio, Laszlo Urban, Clarisse Audigier-Valette, Lorena Lupinacci, Randeep Sangha, Adam Pluzanski, Jacobus Burgers, Mauricio Mahave, Samreen Ahmed, Adam J Schoenfeld, Luis G Paz-Ares, Martin Reck, Hossein Borghaei, Kenneth J O'Byrne, Ravi G Gupta, Judith Bushong, Li Li, Steven I Blum, Laura J Eccles, Suresh R Ramalingam
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer in CheckMate 227. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Hossein Borghaei, Scott N Gettinger, Everett E Vokes, Laura Q M Chow, Marco Angelo Burgio, Javier De Castro Carpeño, Adam Pluzanski, Arrieta Oscar, Osvaldo Arén Frontera, Rita Chiari, Charles Butts, Joanna Wójcik-Tomaszewska, Bruno Coudert, Marina Chiara Garassino, Neal Ready, Enriqueta Felip Font, Miriam Alonso García, David Michael Waterhouse, Manuel Dómine, Fabrice Barlesi, Scott Antonia, Markus Wohlleber, David E Gerber, Grzegorz Czyzewicz, David R Spigel, Lucio Crino, Wilfried Enst Erich Eberhardt, Ang Li, Sathiya Marimuthu, Julie Brahmer
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (7) (2021)
Hossein Borghaei, Corey J Langer, Luis Paz-Ares, Delvys Rodríguez-Abreu, Balazs Halmos, Marina C Garassino, Baerin Houghton, Takayasu Kurata, Ying Cheng, Jianxin Lin, M Catherine Pietanza, Bilal Piperdi, Shirish M Gadgeel
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. Cancer 126 (22) (2020)
Timothy F Burns, Hossein Borghaei, Suresh R Ramalingam, Tony S Mok, Solange Peters
Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 38 (35) (2020)
Hermann Einsele, Hossein Borghaei, Robert Z Orlowski, Marion Subklewe, Gail J Roboz, Gerhard Zugmaier, Peter Kufer, Karim Iskander, Hagop M Kantarjian
The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer 126 (14) (2020)
J Nicholas Bodor, Yanis Boumber, Hossein Borghaei
Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC). Cancer 126 (2) (2019)

Hossein Borghaei.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Hossein Borghaei